TrialHaematologica2022

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.

Rami S Komrokji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.